Pneumocystis jiroveciipneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient
Author:
Publisher
Wiley
Subject
Infectious Diseases,Transplantation
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-3062.2008.00345.x/fullpdf
Reference18 articles.
1. 1. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004; 4 (Suppl 10): 135-141.
2. 2. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-866.
3. 3. Becker YT , Samaniego-Picota M , Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621-628.
4. 4. Becker YT , Becker BN , Pirsch JD , Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
5. 5. Venhuizen AC , Hustinx WN , van Houte AJ , Veth G , van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008; 80: 275-276. Epub Nov 15, 2007.
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06
2. Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives;Current Pharmaceutical Design;2020-08-31
3. Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient and Literature Review;Infection and Drug Resistance;2020-08
Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient and Literature Review
4. Successful launch of an ABO-incompatible kidney transplantation program to overcome the shortage of compatible living donors: experience at a single center;Clinical Nephrology;2017-09-01
5. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment;Clinical Transplantation;2017-08-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3